Replies to post #119932 on Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

And then there was Aruda. Whoopsie! Look on the bright side, those shares weren't dilutive.

[F1ash]

Let's make this simple. Daptomycin generates One BILLION dollars a year in revenue. It take 7 IV doses to accomplish what Brilacidin does in ONE.


An APPRV just sold for $350 million. Kevetrin was very effective in the mouse models for Retinoblastoma.

The current market cap for Cellceutix is only ~ 200 million.

And then there is Prurisol and Kevetrin for ovarian cancer and a preclinical for Autism and TB etc.

Do your DD, figure the likelihood of at least partial success in the upcoming trials, discount those likely future revenues to their current value. Wait patiently for everyone else to figure it out. Much less stressful.

[Loose Lips]

I hate to admit it, but it appears to me that CTIX is "guilty until proven innocent". There is kind of a perfect storm of outsider lies/misinformation, inherent biotech risk, slow PH1 K trial progress, pink sheet bias, and the fact that the drug pipeline almost can be classified as 'too good to be true' that is keeping a lot of investment on the sidelines. CTIX still has to "prove" itself the skeptics and the risk adverse investors who are content to wait for more concrete results before they jump in. Once we get some final trial data in hand from B-OM, B-PH3, and K-ph3 i think it will finally turn pps around. At this stage for us longs it continues to be a test of patience. CTIX is getting there, slow and steady.

[scottsmith]

Some simple, straight forward FUD. 30 months is a good long while to wait I'll give you that. Our short term share price problems will be over when K P1 wraps up and we start partnering up. Whether P1 ends in a month or a year I can't say.